Jong Hyuk Yoon1, Dayea Kim2, Jaeyoon Kim3,4, Hyeongjoo Lee4, Jaewang Ghim4, Byung Jun Kang5, Parkyong Song5, Pann-Ghill Suh6, Sung Ho Ryu5, Taehoon G Lee7. 1. Department of Neural Development and Disease, Korea Brain Research Institute, Daegu, Republic of Korea taehoon@novacelltech.com jhyoon@kbri.re.kr. 2. New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Republic of Korea. 3. School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea. 4. NovaCell Technology, Inc., Pohang, Republic of Korea. 5. Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea. 6. School of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea. 7. NovaCell Technology, Inc., Pohang, Republic of Korea taehoon@novacelltech.com jhyoon@kbri.re.kr.
Abstract
BACKGROUND: There are limitations to current colorectal cancer (CRC)-specific diagnostic methods and therapies. Tumorigenesis proceeds because of interaction between cancer cells and various surrounding cells; discovering new molecular mediators through studies of the CRC secretome is a promising approach for the development of CRC diagnostics and therapies. MATERIALS AND METHODS: A comparative secretomic analysis was performed using primary and metastatic human isogenic CRC cells. Proliferation was determined by MTT and thymidine incorporation assay, migration was determined by wound-healing assay (ELISA). The level of palmitoleoyl-protein carboxylesterase (NOTUM) in plasma from patients with CRC was determined by enzyme-linked immunosorbent assay. RESULTS: NOTUM expression was increased in metastatic cells. Proliferation was suppressed by inhibiting expression of NOTUM. Knockdown of NOTUM genes inhibited proliferation as well as migration, with possible involvement of p38 and c-JUN N-terminal kinase in this process. The result was verified in patients with CRC. CONCLUSION: NOTUM may be a new candidate for diagnostics and therapy of CRC. Copyright
BACKGROUND: There are limitations to current colorectal cancer (CRC)-specific diagnostic methods and therapies. Tumorigenesis proceeds because of interaction between cancer cells and various surrounding cells; discovering new molecular mediators through studies of the CRC secretome is a promising approach for the development of CRC diagnostics and therapies. MATERIALS AND METHODS: A comparative secretomic analysis was performed using primary and metastatic human isogenic CRC cells. Proliferation was determined by MTT and thymidine incorporation assay, migration was determined by wound-healing assay (ELISA). The level of palmitoleoyl-protein carboxylesterase (NOTUM) in plasma from patients with CRC was determined by enzyme-linked immunosorbent assay. RESULTS:NOTUM expression was increased in metastatic cells. Proliferation was suppressed by inhibiting expression of NOTUM. Knockdown of NOTUM genes inhibited proliferation as well as migration, with possible involvement of p38 and c-JUN N-terminal kinase in this process. The result was verified in patients with CRC. CONCLUSION:NOTUM may be a new candidate for diagnostics and therapy of CRC. Copyright
Authors: Felix B Engel; Michael Schebesta; Mychelle T Duong; Gang Lu; Shuxun Ren; Jeffery B Madwed; Huiping Jiang; Yibin Wang; Mark T Keating Journal: Genes Dev Date: 2005-05-03 Impact factor: 11.361
Authors: Sérgia Velho; Carla Oliveira; Ana Ferreira; António Carlos Ferreira; Gianpaolo Suriano; Simó Schwartz; Alex Duval; Fátima Carneiro; José Carlos Machado; Richard Hamelin; Raquel Seruca Journal: Eur J Cancer Date: 2005-07 Impact factor: 9.162
Authors: Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Elliott D Bayle; Fredrik Svensson; Benjamin N Atkinson; David Steadman; Nicky J Willis; Hannah L Woodward; Paul Whiting; Jean-Paul Vincent; Paul V Fish Journal: J Med Chem Date: 2021-03-30 Impact factor: 7.446